A Phase 3 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Placebo Comparator in Dry Eye Disease, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one has the largest enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 4th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2021.
This study's enrollment of 757 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 158 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one has the largest enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 6th registered.
Aldeyra Therapeutics, Inc.’s Dry Eye Syndromes studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Aldeyra Therapeutics, Inc.’s 13 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproxalap four times daily (QID) for four weeks followed by two times daily (BID) for two weeks
Drug: Reproxalap Ophthalmic Solution (0.25%)
Vehicle QID for four weeks followed by BID for two weeks
Drug: Placebo Comparator
Reproxalap (0.25%) QID for four weeks followed by BID for 11 months
Drug: Reproxalap Ophthalmic Solution (0.25%)
Vehicle QID for four weeks followed by BID for 11 months
Drug: Placebo Comparator
Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease
The proportion of 6-week safety population subjects that experience at least one visual acuity TE-SAE decrease (defined as an increase of 0.22 or greater in logMAR score) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (six weeks)
TE-SAEs of Increase in Intraocular Pressure
The proportion of 6-week safety population subjects that experience at least one intraocular pressure TE-SAE (increase from baseline of greater than or equal to 10 mmHg and intraocular pressure of greater than 25 mmHg) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (six weeks)
TE-SAEs of the Cornea
The proportion of 6-week safety population subjects that experience at least one cornea-related TE-SAE (detected via slit-lamp examination) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (six weeks)
TE-SAEs of the Retina
The proportion 6-week safety population subjects that experience at least one retinal TE-SAE (detected via fundoscopy) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (six weeks)
TE-SAEs of Visual Acuity Decrease
The proportion of 12-month safety population subjects that experience at least one visual acuity TE-SAE (defined as an increase of 0.22 or greater in logMAR score) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (12 months)
TE-SAEs of Increase in Intraocular Pressure
The proportion of 12-month safety population subjects that experience at least one intraocular pressure TE-SAE (increase from baseline of greater than or equal to 10 mmHg and intraocular pressure of greater than 25 mmHg) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (12 months)
TE-SAEs of the Cornea
The proportion of 12-month safety population subjects that experience at least one cornea-related TE-SAE (detected via slit-lamp examination) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (12 months)
TE-SAEs of the Retina
The proportion 12-month safety population subjects that experience at least one retinal TE-SAE(detected via fundoscopy) categorized as probably or definitely related to test article.
Time frame: Safety assessment period (12-months)
| Milestone | Reproxalap | Vehicle |
|---|---|---|
| Started | 504 | 253 |
| As treated | 501 | 250 |
| Completed | 273 | 161 |
| Not completed | 231 | 92 |
| Withdrew: Lost to follow-up | 46 | 24 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Not detailed | 1 | 2 |
| Withdrew: Withdrawal by subject | 71 | 28 |
| Withdrew: Adverse event | 56 | 7 |
| Withdrew: Protocol violation | 6 | 1 |
| Withdrew: Trial terminated by sponsor | 49 | 29 |
The proportion of 6-week safety population subjects that experience at least one visual acuity TE-SAE decrease (defined as an increase of 0.22 or greater in logMAR score) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease | 0 | 0 |
The proportion of 6-week safety population subjects that experience at least one intraocular pressure TE-SAE (increase from baseline of greater than or equal to 10 mmHg and intraocular pressure of greater than 25 mmHg) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of Increase in Intraocular Pressure | 0 | 0 |
The proportion of 6-week safety population subjects that experience at least one cornea-related TE-SAE (detected via slit-lamp examination) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of the Cornea | 0 | 0 |
The proportion 6-week safety population subjects that experience at least one retinal TE-SAE (detected via fundoscopy) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of the Retina | 0 | 0 |
Overall change from baseline in visual acuity logMAR score. Visual acuity values were averaged across both eyes for each participant.
| LogMAR | Reproxalap | Vehicle |
|---|---|---|
| Change From Baseline in Visual Acuity | -0.030 ± 0.0035 | -0.016 ± 0.0046 |
The proportion of 12-month safety population subjects that experience at least one visual acuity TE-SAE (defined as an increase of 0.22 or greater in logMAR score) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of Visual Acuity Decrease | 0 | 0 |
The proportion of 12-month safety population subjects that experience at least one intraocular pressure TE-SAE (increase from baseline of greater than or equal to 10 mmHg and intraocular pressure of greater than 25 mmHg) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of Increase in Intraocular Pressure | 0 | 0 |
The proportion of 12-month safety population subjects that experience at least one cornea-related TE-SAE (detected via slit-lamp examination) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of the Cornea | 0 | 0 |
The proportion 12-month safety population subjects that experience at least one retinal TE-SAE(detected via fundoscopy) categorized as probably or definitely related to test article.
| Participants | Reproxalap | Vehicle |
|---|---|---|
| TE-SAEs of the Retina | 0 | 0 |
Collected over Safety assessment period (6 weeks or 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reproxalap (6-week) | 0/503 (0%) | 0/503 (0%) | 205/503 (40.8%) |
| Vehicle (6-week) | 0/251 (0%) | 0/251 (0%) | 8/251 (3.2%) |
| Reproxalap (12-month) | 0/299 (0%) | 3/299 (1%) | 127/299 (42.5%) |
| Vehicle (12-month) | 2/148 (1.4%) | 5/148 (3.4%) | 3/148 (2%) |
| Event | Reproxalap (6-week) | Vehicle (6-week) | Reproxalap (12-month) | Vehicle (12-month) |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/503 | 0/251 | 0/299 | 1/148 |
| COVID-19 InfectionInfections and infestations | 0/503 | 0/251 | 0/299 | 1/148 |
| Unknown cause of deathGeneral disorders | 0/503 | 0/251 | 0/299 | 1/148 |
| Premature ventricular contractionsCardiac disorders | 0/503 | 0/251 | 0/299 | 1/148 |
| Unstable AnginaCardiac disorders | 0/503 | 0/251 | 0/299 | 1/148 |
| Worsening coronary artery diseaseCardiac disorders | 0/503 | 0/251 | 0/299 | 1/148 |
| Right tonsil squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/503 | 0/251 | 0/299 | 1/148 |
| Worsening of chronic back painMusculoskeletal and connective tissue disorders | 0/503 | 0/251 | 1/299 | 0/148 |
| Kidney infectionInfections and infestations | 0/503 | 0/251 | 1/299 | 0/148 |
| Supraventricular TachycardiaCardiac disorders | 0/503 | 0/251 | 1/299 | 0/148 |
| Event | Reproxalap (6-week) | Vehicle (6-week) | Reproxalap (12-month) | Vehicle (12-month) |
|---|---|---|---|---|
| General disorders and administration site conditionsGeneral disorders | 205/503 | 8/251 | 127/299 | 3/148 |
6-week safety population
| Age, Categorical(Participants) | Reproxalap (6-week) | Vehicle (6-week) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 336 | 165 | 501 |
| >=65 years | 167 | 86 | 253 |
| Age, Continuous(years) | Reproxalap (6-week) | Vehicle (6-week) | Total |
|---|---|---|---|
| Mean | 55.7 ± 15.8 | 56.9 ± 15.8 | 56.0 ± 15.75 |
| Sex: Female, Male(Participants) | Reproxalap (6-week) | Vehicle (6-week) | Total |
|---|---|---|---|
| Female | 356 | 176 | 532 |
| Male | 147 | 75 | 222 |
| Ethnicity (NIH/OMB)(Participants) | Reproxalap (6-week) | Vehicle (6-week) | Total |
|---|---|---|---|
| Hispanic or Latino | 154 | 75 | 229 |
| Not Hispanic or Latino | 349 | 176 | 525 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Reproxalap (6-week) | Vehicle (6-week) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 28 | 15 | 43 |
| Asian | 68 | 42 | 110 |
| Black or African American | 54 | 26 | 80 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 343 | 162 | 505 |
| Other | 1 | 2 | 3 |
| Multiple | 8 | 4 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Oct 2022, 20 months.
Results were first posted in Nov 2025, 3 years 1 month after primary completion. A results delay was requested in May 2023.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 20 months is above that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap